<DOC>
	<DOCNO>NCT02687139</DOCNO>
	<brief_summary>In study investigator aim evaluate diagnostic utility PSMA-targeted 18F-DCFPyL PET/CT patient renal cell carcinoma .</brief_summary>
	<brief_title>Study PSMA-targeted 18F-DCFPyL PET/CT Evaluation Patients With Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<criteria>Clinically diagnose histologically proven stage IIIV renal cell carcinoma Completed stag evaluation compute tomography ( CT ) magnetic resonance imaging ( MRI ) chest , abdomen pelvis â‰¤90 day prior study enrollment History malignancy diagnose within last 3 year ( exception low risk prostate cancer , ductal carcinoma situ breast , squamous cell carcinoma basal cell carcinoma skin ) Administered radioisotope within 5 physical halflives prior study enrollment Pregnancy ( ( determine accordance policy positron emission tomography ( PET ) center ) ) Intention enroll blind therapeutic clinical trial follow Positron emission tomographycomputed tomography ( PET/CT )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>